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Background
To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant
chemotherapy) in patients with early stage non-small cell lung cancer (NSCLC),we performed two systematic reviews andmeta-analyses
of all randomised controlled trials using individual participant data. Results were first published in The Lancet in 2010.
Objectives
To compare, in terms of overall survival, time to locoregional recurrence, time to distant recurrence and recurrence-free survival:
A. Surgery versus surgery plus adjuvant chemotherapy
B. Surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapy
in patients with histologically diagnosed early stage NSCLC.
(2)To investigate whether or not predefined patient subgroups benefit more or less from cisplatin-based chemotherapy in terms of
survival.
Search methods
We supplemented MEDLINE and CANCERLIT searches (1995 to December 2013) with information from trial registers, hand-
searching relevant meeting proceedings and by discussion with trialists and organisations.
Selection criteria
We included trials of a) surgery versus surgery plus adjuvant chemotherapy; and b) surgery plus radiotherapy versus surgery plus
radiotherapy plus adjuvant chemotherapy, provided that they randomised NSCLC patients using a method which precluded prior
knowledge of treatment assignment.
Data collection and analysis
We carried out a quantitative meta-analysis using updated information from individual participants from all randomised trials. Data
from all patients were sought from those responsible for the trial. We obtained updated individual participant data (IPD) on survival,
and date of last follow-up, as well as details of treatment allocated, date of randomisation, age, sex, histological cell type, stage, and
performance status. To avoid potential bias, we requested information for all randomised patients, including those excluded from the
investigators’ original analyses. We conducted all analyses on intention-to-treat on the endpoint of survival. For trials using cisplatin-
based regimens, we carried out subgroup analyses by age, sex, histological cell type, tumour stage, and performance status.
Main results
We identified 35 trials evaluating surgery plus adjuvant chemotherapy versus surgery alone. IPD were available for 26 of these trials
and our analyses are based on 8447 participants (3323 deaths) in 34 trial comparisons. There was clear evidence of a benefit of adding
chemotherapy after surgery (hazard ratio (HR)= 0.86, 95% confidence interval (CI)= 0.81 to 0.92, p< 0.0001), with an absolute
increase in survival of 4% at five years.
We identified 15 trials evaluating surgery plus radiotherapy plus chemotherapy versus surgery plus radiotherapy alone. IPD were
available for 12 of these trials and our analyses are based on 2660 participants (1909 deaths) in 13 trial comparisons. There was
also evidence of a benefit of adding chemotherapy to surgery plus radiotherapy (HR= 0.88, 95% CI= 0.81 to 0.97, p= 0.009). This
represents an absolute improvement in survival of 4% at five years.
For both meta-analyses, we found similar benefits for recurrence outcomes and there was little variation in effect according to the type
of chemotherapy, other trial characteristics or patient subgroup.
We did not undertake analysis of the effects of adjuvant chemotherapy on quality of life and adverse events. Quality of life information
was not routinely collected during the trials, but where toxicity was assessed and mentioned in the publications, it was thought to be
manageable. We considered the risk of bias in the included trials to be low.
Authors’ conclusions
Results from 47 trial comparisons and 11,107 patients demonstrate the clear benefit of adjuvant chemotherapy for these patients,
irrespective of whether chemotherapy was given in addition to surgery or surgery plus radiotherapy. This is the most up-to-date and
complete systematic review and individual participant data (IPD) meta-analysis that has been carried out.
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P L A I N L A N G U A G E S U M M A R Y
Chemotherapy after surgery for early stage non-small cell lung cancer
Review question
Do patients with non-small cell lung cancer live longer if they are given chemotherapy after surgery?
Background
Non-small cell lung cancer is the most common type of lung cancer. If the tumour is early stage, not too big and has not spread to
other parts of the body, doctors usually operate to remove it. At the same time, they will also remove a bit of the lung, or the entire lung
that has the tumour. They may also give radiotherapy (treatment with x-rays) after the operation, aiming to kill any remaining cancer
cells. They may also give chemotherapy (drug treatment) after surgery to lower the risk of the cancer coming back. This treatment is
called adjuvant chemotherapy.
In 1995, we did a systematic review andmeta-analysis of individual participant data looking at adjuvant chemotherapy and surgery (with
or without radiotherapy). It brought together information from all patients who took part in similar trials. These trials compared what
happened to people with non-small cell lung cancer who were given chemotherapy after surgery (with or without radiotherapy) with
those who had surgery without chemotherapy (with or without radiotherapy). We found that it was not clear whether chemotherapy
helped patients with non-small cell lung cancer live longer.
Since this study was completed, many new trials have been done. Therefore, we carried out a new systematic review and meta-analysis
of individual participant data that included all trials, old and new. This study aimed to find out if giving chemotherapy after surgery
(with or without radiotherapy) can a) help patients live longer, b) stop the cancer coming back (recurrence), and c) stop the cancer
spreading to other parts of the body (metastases).
We carried out two studies called meta-analyses that included patients with non-small cell lung cancer that took part in randomised
controlled trials comparing:
a) surgery versus surgery plus adjuvant chemotherapy; and
b) surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapy.
Results were first published in the Lancet in 2010.
Study characteristics
We searched for relevant trials up to December 2013. The studies brought together trial data from all over the world with 26 trials
(34 trial comparisons) and 8447 patients in the first meta-analysis (surgery versus surgery plus adjuvant chemotherapy); and 12 trials
(13 trial comparisons) and 2660 patients in the second meta-analysis (surgery plus radiotherapy versus surgery plus radiotherapy plus
adjuvant chemotherapy). Trials were carried out between 1979 and 2003.
Key results
Results found that people with non-small cell lung cancer that had surgery followed by chemotherapy (with or without radiotherapy),
lived longer than those who had surgery without chemotherapy (with or without radiotherapy).
After five years, 64 out of every 100 patients who were given chemotherapy after surgery were alive compared to 60 patients out of
every 100 who just had surgery. For those who also received radiotherapy, after five years, 33 out of every 100 patients who received
chemotherapy, surgery and radiotherapy were alive compared to 29 out of every 100 patients who received surgery and radiotherapy.
Quality of life information was not routinely collected during the trials, but where toxicity was assessed and mentioned in the
publications, it was thought to be manageable.
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In both studies, there was little variation in the effect of chemotherapy according to the type of chemotherapy given, other trial
characteristics, or by the type of patient included in the trial.
Quality of evidence
These systematic reviews and meta-analyses use individual participant data, which is considered the gold standard of this type of review.
We included all eligible trials if possible, no matter what language they were published in or whether they were published or not. The
first meta-analysis (surgery versus surgery plus adjuvant chemotherapy) included 92% of all patients in eligible trials and the second
meta-analysis (surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapy) included 86% of all patients in
eligible trials.
We are confident that further research is unlikely to change the findings. The studies were well designed and conducted, address the
review question, and the effects are consistent across trials. The impact of any data we have not been able to include in our analyses is
small.
B A C K G R O U N D
Description of the condition
Worldwide, around 1.5 million new cases of lung cancer are di-
agnosed annually (Parkin 2005), and approximately 85% of such
cases are non-small cell lung cancer (NSCLC).(American Cancer
Society 2007). Although surgery is regarded as optimal treatment,
only 20% to 25% of tumours are suitable for potentially cura-
tive resection (Datta 2003), therefore other treatments are also
used. Our previous individual participant data (IPD) meta-anal-
yses (NSCLC Collaborative Group 1995), gave evidence that cis-
platin-based chemotherapy after surgery might prolong survival
(hazard ratio (HR)] = 0.87, 95% confidence interval (CI)= 0.74 to
1.02, p= 0.08). With fewer trials and patients, the value of chemo-
therapy following surgery plus postoperative radiotherapy was less
clear (NSCLC Collaborative Group 1995). Recent meta-analyses
(Berghmans 2005; Bria 2005; Hamada 2005;Hotta 2004; Pignon
2008; Sedrakyan 2004) showing significant survival benefits with
adjuvant chemotherapy, that is chemotherapy given after surgery,
have included a variety of trials and patients (Table 1).
Description of the intervention
This review concentrated on randomised controlled trials that had
tested surgery alone with drug treatment (chemotherapy) with or
with out radiotherapy after surgery. These trials mainly used cis-
platin-based chemotherapy, this is commonly used for treatment
of lung cancer as well as other cancers. Some trials, mainly those
that took place in Asia, used UFT (also called tegafur/uracil) che-
motherapy.
How the intervention might work
If the tumour is early stage, for example, not too big and has
not spread to other parts of the body, doctors usually operate to
remove it. At the same time, they will also remove a bit of the
lung, or the entire lung that has the tumour. They may also give
radiotherapy after the operation, aiming to kill any remaining
cancer cells. They may also give chemotherapy after surgery to
lower the risk of the cancer coming back. This treatment is called
adjuvant chemotherapy.
Why it is important to do this review
The aim of this review was to assess more reliably the effects of ad-
juvant chemotherapy, with or without postoperative radiotherapy,
in two new comprehensive IPD meta-analyses. Contrary to our
previous meta-analyses, the present study is restricted to patients
with early stage disease.
Results of these two meta-analyses were first published in The
Lancet in 2010 (NSCLC Meta-analysis Collaborative Group
2010).
O B J E C T I V E S
To compare, in terms of overall survival, time to locoregional re-
currence, time to distant recurrence and recurrence-free survival:
A. Surgery versus surgery plus adjuvant chemotherapy
B. Surgery plus radiotherapy versus surgery plus radiotherapy plus
adjuvant chemotherapy
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in patients with histologically diagnosed early stage non-small cell
lung cancer.
(2)To investigate whether or not predefined patient subgroups
benefit more or less from cisplatin-based chemotherapy in terms
of survival.
Part A was carried out by the MRC CTU at UCL in London,
UK and Part B was carried out by the Institute Gustave Roussy,
Villejuif, France.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To be included, both published and unpublished completed trials
had to be properly randomised using established methods (not
quasi-randomised). Trials could not have been confounded by ad-
ditional therapeutic differences between the two arms and must
have commenced randomisation on or after 1 January 1965. Tri-
als should have aimed to include patients who had undergone a
potentially curative resection and not received previous chemo-
therapy. For the first meta-analysis, trials should have compared
surgery versus surgery plus adjuvant chemotherapy. For the sec-
ond, trials should have compared surgery plus radiotherapy ver-
sus surgery plus radiotherapy plus adjuvant chemotherapy.We ex-
cluded trials using long-term alkylating agents for more than a
year because these are no longer used to treat non-small cell lung
cancer (NSCLC), and have been shown to be harmful (NSCLC
Collaborative Group 1995).
Types of participants
Eligible trials included individuals with histologically confirmed
NSCLC who had undergone a potentially curative resection. We
included individual participant data from all randomised patients
in the meta-analyses, and where possible obtained data for indi-
viduals who had been excluded from the original trial analyses.
We excluded from the meta-analyses patients with small cell lung
cancer that were included in early trials that randomised all types
of lung cancer.
Types of interventions
We classified trials as belonging to one of the following categories
of chemotherapy.
• Surgery versus surgery plus adjuvant chemotherapy
◦ platinum plus vinca alkaloid/etoposide
◦ platinum plus vinorelbine
◦ platinum plus taxane
◦ other platinum regimens
◦ platinum plus vinca alkaloid plus tegafur and uracil/
tegafur
◦ tegafur and uracil/tegafur plus other agent
◦ tegafur and uracil/tegafur
• Surgery plus radiotherapy versus surgery plus radiotherapy
plus adjuvant chemotherapy
◦ platinum plus vinca alkaloid/etoposide
◦ platinum plus vinorelbine
◦ other platinum regimens
◦ antimetabolic agent only
Types of outcome measures
.
Primary outcomes
The primary outcome was overall survival, defined as the time
from randomisation until death by any cause. Living patients were
censored on the date of last follow-up
Secondary outcomes
Recurrence-free survival was defined as the time from randomi-
sation until first recurrence, or death by any cause. Patients alive
without disease were censored on the date of last follow-up. To
avoid bias from under-reporting of subsequent events, time to lo-
coregional recurrence was defined as the time from randomisa-
tion until first locoregional recurrence, with patients experiencing
earlier distant recurrences being censored at the time of distant
recurrence. Similarly, for time to distant recurrence, patients ex-
periencing earlier locoregional recurrences were censored on that
date. Patients who died without recurrence were censored on date
of death. Data on quality of life and adverse events were not rou-
tinely collected in the trials and therefore could not be analysed in
this review.
Search methods for identification of studies
To limit publication bias, we included published and unpub-
lished trials with no restriction based on language. We carried
out searches of MEDLINE and CANCERLIT from 1995 (using
The Cochrane Collaboration’s optimal strategy (Lefebvre 2001;
Lefebvre 2008).We supplemented trial registers by handsearches
of conference proceedings and reference lists of trial publications
and review articles. We asked our collaborators if they knew of
additional trials. We carried out initial searches in 2003 and reg-
ularly updated these; we carried out the most recent searches in
December 2013.
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Electronic searches
WemodifiedTheCochraneCollaboration’s optimum search strat-
egy for retrieving randomised controlled trials (RCTs) fromMED-
LINE (Appendix 1) to specifically retrieve RCTs of chemotherapy
for NSCLC and used this search strategy to search MEDLINE
and CANCERLIT (1995 to 2013).
In addition, we searched the following electronic bibliographic
databases.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (1995 to 2013)
• Proceedings of American Society for Clinical Oncology
(ASCO) (1995 to 2013)
We used the following trial registers to supplement searches of
electronic databases with trials that were not (yet) published or
were still recruiting patients.
• United Kingdom Coordinating Committee on Cancer
Research (UKCCCR) Trials Register
• ClinicalTrials.gov
• Physicians Data Query Protocols (open and closed)
• Current Controlled Trials ‘metaRegister’ of controlled trials
Searching other resources
Handsearches
We carried out the following handsearches to identify trials that
may have only been reported as abstracts or that might have been
missed in the searches described above.
• Proceedings of the American Society for Clinical Oncology
(ASCO) 1993 to 1994
• Proceedings of the International Association for the Study
of Lung Cancer (IASLC) World Lung Cancer Conference 1997
to 2013
• Proceedings of the European Society of Medical Oncology
(ESMO) 1996 to 2013
• Proceedings of the European Cancer Conference
Organization (ECCO) 1995 to 2013
Reference lists
We searched bibliographies of all identified trials and review arti-
cles.
Correspondence
We asked all participating trialists to review and supplement a
provisional list of trials.
Data collection and analysis
Selection of studies
Four Members of the Project Management Group (SB, AA, JPP,
LA) checked all titles and abstracts, identified by both electronic
searching and handsearching of conference proceedings, and ob-
tained the full publications for those thought to be potentially
relevant. We sought individual participant data (IPD) from trial
authors, including updated follow-up, where available.
Data extraction and management
We sought individual participant data for all eligible trials. For the
15 trials originally included in the 1995 analysis of the NSCLC
Collaborative Group, we only sought updated follow-up. For new
trials, we sought data on age, sex, extent of resection, patholog-
ical tumour stage, histology, performance status, treatment arm,
date of randomisation, recurrence, survival and follow-up for all
patients randomised.
We used standard checks to identify missing data. We verified the
data, for example, by checking the order of the dates, and assessed
data validity and consistency. To assess randomisation integrity, we
checked patterns of treatment allocation and balance of baseline
characteristics by treatment arm.We checked follow-up of surviv-
ing patients to ensure that it was balanced by treatment arm and
up-to-date. We resolved any queries and each trial investigator or
statistician verified the final database.
Project co-ordination
Two teams co-ordinated the project management. Each team col-
lected and checked data and analysed results for their comparison
as follows:
• Team A: surgery versus surgery plus adjuvant chemotherapy
(MRC CTU at UCL, London, UK);
• Team B: surgery plus radiotherapy versus surgery plus
radiotherapy plus adjuvant chemotherapy (Institut Gustave
Roussy, Villejuif, France).
Assessment of risk of bias in included studies
We assessed the included studies using The Cochrane Collabora-
tion’s ’Risk of bias’ tool outlined in Table 8.5c of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins
2011) and these studies were checked by a second review author.
We considered adequate sequence generation and allocation con-
cealment to be most important and therefore a judgement of low
risk was desirable for these domains for all trials. Blinding was
not appropriate due to the nature of the treatments and any issues
surrounding the reporting of incomplete outcome data, selective
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outcome reporting or attrition bias were overcome by the collec-
tion of IPD.
Measures of treatment effect
Unless otherwise stated, we prespecified all analyses in the proto-
cols, and carried out on an intention-to-treat analysis. For each
outcome, we used the logrank expected number of events and
variance to calculate individual trial hazard ratios (HRs), which
were pooled across trials using the fixed-effect model. We pre-
sented overall survival using simple (non-stratified) Kaplan-Meier
curves. We computed the median follow-up for all patients using
the reverse Kaplan-Meier method (Schemper 1996).
To explore any impact of trial characteristics on the effect of adju-
vant chemotherapy on overall survival, we calculated pooled HRs
for each prespecified trial group and used Chi2 tests for interaction
to investigate differences in the treatment effect across these trial
groups.
We calculated absolute differences in overall survival at five years
using overall HRs and control group survival. If we identified a
difference in effect by trial group or patient subgroup, we used
HRs and control group survival for the relevant groups to calculate
absolute differences; otherwise we used the overall HR.
As two trials compared two adjuvant chemotherapy regimens with
one control arm,we compared each treatment armwith the control
arm and analysed these as separate trial comparisons in different
chemotherapy categories (A22 WJSG 2 (1+3); A25 ACTLC4a;
A29 WJSG2 (2+3); A33 ACTLC4b). To avoid double-counting
the control arms in the overall and subgroup analyses, however,
we combined the treatment arms and compared them with the
relevant control arm. Because of this, there are no overall totals in
Figure 1. For other trials that belonged in different chemotherapy
categories (A06 ALPI1; B06 ALPI2), different meta-analyses or
both (A07 IALT1; A08 BLT1; A12 IALT2; A13 BLT2; A18 BLT3;
A20 OLCSG1c; A27 OLCSG1b; A28 OLCSG1a; B07 IALT3;
B08 BLT4; B10 IALT4; B13 OLCSG1d) we compared relevant
patients from the treatment arm with the corresponding control
arm patients, and analysed them as separate trial comparisons.
This gives a greater number of trial comparisons than there are
trials.
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Figure 1. For all chemotherapy groups, HR 0.86 (0.81 to 92); p< 0.0001Forest plot of comparison: 1 surgery
versus surgery + chemotherapy, outcome: 1.1 survival.
8Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dealing with missing data
We outlined all desired variables in a protocol (available on request
from SB). We requested any missing variables from those who
carried out the trial.
Assessment of heterogeneity
We used Chi2 tests and the I2 statistic to test for differences in the
treatment effect across groups of trials or groups of patients.
Assessment of reporting biases
As we collected IPD, we did not encounter any reporting biases.
Data synthesis
Where we could get data, we included all eligible trials in the
analyses. The analyses were carried out in RevMan (RevMan
2014).
Subgroup analysis and investigation of heterogeneity
To investigate differences in the treatment effect across patient
subgroups, we undertook Cox regressions, including the relevant
treatment by subgroup interaction term within trials and the in-
teraction coefficients (HRs) pooled across trials (Fisher 2011). We
investigated whether there were differences in the treatment effect
depending upon the patients’ age, sex, histological cell type, tu-
mour stage, or performance status.
Sensitivity analysis
We outlined in the protocol that HRs for overall survival would
be calculated, excluding any trials that were clear outliers.
R E S U L T S
Description of studies
Surgery versus surgery plus adjuvant chemotherapy
We identified 35 eligible trials. We included 26 trials; nine from
the 1995 meta-analysis and 17 additional ones (see Characteristics
of included studies). We could not include nine trials because
data were not available for three published (Ayoub 1991; Clerici
1991; Ichinose 1991) and two unpublished trials (EORTC08922;
NCCTG 852451) (see Characteristics of excluded studies); ade-
quate contact with the investigators could not be established for
two trials (Ueda 2004; Zarogoulidis 1996) and two other tri-
als had only recently been presented (Wang 2009; Wu 2009).
Therefore, we included data from 26 published trials, allowing 34
trial comparisons (A01 IPCR, Chiba; A02 JLCSSG; A03 Mineo;
A04 Park1; A05 Park2; A06 ALPI1; A07 IALT1; A08 BLT1;
A09 JCOG 9304; A10 ANITA1; A11 JBR10; A12 IALT2; A13
BLT2; A14 CALGB 9633; A15 LCSG 801; A16 FLCSG 1; A17
LCSG853; A18 BLT3; A19 SGACLCACTLC1; A20OLCSG1c;
A21 SGACLC ACTLC2; A22 WJSG 2 (1+3); A23 WJSG3;
A24 Xu; A25 ACTLC4a; A26 OLCSG2b; A27 OLCSG1b; A28
OLCSG1a; A29 WJSG2 (2+3); A30 WJSG4; A31 NJSGLCS;
A32 OLCSG2a; A33 ACTLC4b; A34 JLCRG).
Platinum-based chemotherapy, without tegafur plus uracil or tega-
fur alone was used in 18 trial comparisons (A01 IPCR, Chiba; A02
JLCSSG; A03 Mineo; A04 Park1; A05 Park2; A06 ALPI1; A07
IALT1; A08 BLT1; A09 JCOG 9304; A10 ANITA1; A11 JBR10;
A12 IALT2; A13 BLT2; A14 CALGB 9633; A15 LCSG 801;
A16 FLCSG 1; A17 LCSG 853; A18 BLT3) and platinum-based
chemotherapy with tegafur or with tegafur plus uracil was used
in eight (A19 SGACLC ACTLC1; A20 OLCSG1c; A21 SGA-
CLC ACTLC2; A22 WJSG 2 (1+3); A23 WJSG3; A24 Xu; A25
ACTLC4a; A26 OLCSG2b). In all but one (A14 CALGB 9633),
cisplatin was the platinum agent. Tegafur or tegafor plus uracil
were used in combination with other agents in one trial compar-
ison (A27 OLCSG1b) and alone in seven (A28 OLCSG1a; A29
WJSG2 (2+3); A30 WJSG4; A31 NJSGLCS; A32 OLCSG2a;
A33 ACTLC4b; A34 JLCRG). Data on histology and stage were
provided for all 34 trial comparisons, age and sex for 33, and per-
formance status for 24 (Table 2). Patients were mostly men with a
median age of 61 years (range 18 to 84). They tended to have good
performance status and tumours that were predominantly stage I-
II adenocarcinomas or squamous cell carcinomas. Staging meth-
ods would have changed over time but the methods used were the
same in both treatment arms in the trials. We combined the small
number of patients with stage IIIB and IV tumours (included for
example, because of misclassification at diagnosis (Table 2), with
stage IIIA patients for analysis; this group is subsequently referred
to as stage III. The median follow-up was 5.5 years.
Surgery plus radiotherapy versus surgery plus radiotherapy
plus adjuvant chemotherapy
We identified 15 eligible trials. We included 12 trials; six from
the 1995 meta-analysis and six additional ones (see Characteristics
of included studies) . We could not include three for the follow-
ing reasons: data were not available for one trial (Ayoub 1991),
and adequate contact with investigators could not be made for
9Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
two trials (Kim 2003; Wolf 2001) (see Characteristics of excluded
studies). Therefore, we included nine published and three unpub-
lished trials, allowing 13 trial comparisons (B01 MSKCC 80-53;
B02 GETCB 01CB82; B03 EORTC 08861; B04 MDA DM
87045; B05 INT 0115; B06 ALPI2; B07 IALT3; B08 BLT4;
B09 ANITA2; B10 IALT4; B11 LCSG 791; B12 FLCSG 3; B13
OLCSG1d).
In nine trial comparisons (B02 GETCB 01CB82; B04MDADM
87045; B06 ALPI2; B07 IALT3; B08 BLT4; B09 ANITA2; B10
IALT4; B12 FLCSG 3; B13OLCSG1d), chemotherapy was given
before radiotherapy, and in four it was given concurrently with
radiotherapy (B01 MSKCC 80-53; B03 EORTC 08861; B05
INT 0115; B11 LCSG 791) . Platinum and a vinca alkaloid or
etoposide were used in 10 trial comparisons (B01MSKCC 80-53;
B02 GETCB 01CB82; B03 EORTC 08861; B04 MDA DM
87045; B05 INT 0115; B06 ALPI2; B07 IALT3; B08 BLT4; B09
ANITA2; B10 IALT4), platinum and tegafur plus uracil/tegafur in
one (B13 OLCSG1d), and other platinum regimens in two trials
(B11 LCSG 791; B12 FLCSG 3). Cisplatin was the sole platinum
agent. Data on age, sex and histology were supplied for all trial
comparisons, stage and extent of resection for 12, and performance
status for 11. Based on these data, patients were mostly men, with
good performance status, a median age of 59 years (range 27 to
81), and stage III, squamous carcinomas. We combined the few
patients with stage IV tumours with stage III patients for analyses,
and referred to this group as stage III. The median follow-up was
6.4 years.
Risk of bias in included studies
We only included trials with adequate methods of randomisation.
We excluded trials using quasi-random methods, such as birth
date. We thoroughly checked all raw data received on individual
patients to ensure both the accuracy of the meta-analysis database
and the quality of randomisation and follow-up. We resolved any
queries and verified the final database entries by discussion with
the responsible trial investigator or statistician. No RCTs were
blinded due to the nature of the intervention, but the primary
outcome is not likely to be influenced by the lack of blinding. We
received IPD for all outcomes of interest, therefore we considered
reporting bias to be low for all RCTs. We considered all included
trials to be at a low risk of bias (see Figure 2 and Figure 3).
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Effects of interventions
Surgery versus surgery plus adjuvant chemotherapy
Overall survival results for the first meta-analysis were based on 34
trial comparisons and 8447 patients (3323 deaths), representing
92%of patientswhowere randomly assigned.The results (Analysis
1.1) show a benefit of adjuvant chemotherapy (hazard ratio (HR)
0.86, 95%confidence interval (CI) 0.81 to 0.92, p<0.0001; Figure
1), with minimum heterogeneity (p=0.40, I² = 4%). This finding
represents an absolute improvement of 4% (95% CI 3 to 6) at five
years, increasing overall survival from 60% to 64% (Figure 4). We
noted a difference in effect by chemotherapy category (interaction
p= 0.06, Figure 1), largely driven by the result of the trial com-
parison,A27 OLCSG1b, that alone constituted the chemotherapy
category for tegafur plus uracil or tegafur plus another agent. A
sensitivity analysis excluding this trial did not suggest that this
drug regimen affects the effect of adjuvant chemotherapy (data
not shown; interaction p= 0.30).
Figure 4. Simple (non-stratified Kaplan-Meier curves for trials of Surgery (S) and chemotherapy (CT)
versus surgery alone and for trials of surgery and chemotherapy and radiotherapy (RT) versus surgery and
radiotherapy.
In view of the differences in the types of chemotherapy used over
time and by geographical region, we grouped trial comparisons by
these characteristics for exploratory analyses. We noted no clear
evidence of a difference in the effect between trial comparisons
included in the 1995 meta-analysis, and those included since this
time (interactionp=0.76), by accrual decade (interactionp=0.61),
or by geographical region (North America, Europe, Asia; interac-
tion p= 0.25; data not shown). Trial comparisons using tegafur
plus uracil or tegafur alone all originated in Asia, and recruited
more women (n = 1293 of 3465 (37%)), and more patients with
stage I tumours (3003/3673 (82%)) of adenocarcinoma histology
(2505/3673 (68%)) than those that did not use tegafur plus uracil
or tegafur alone (1093/4745 (23%)), (2613/4724 (55%)), (1910/
4744 (40%)), respectively.However, we recordedno clear evidence
of a difference in treatment effect between trial comparisons that
did (3848 (45%); HR 0.80, 95% CI 0.71 to 0.90) and those that
did not (4751 (55%); HR 0.89, 95% CI 0.82 to 0.97) use tegafur
plus uracil or tegafur alone (overall HR 0.86, 95% CI 0.81 to
0.92, interaction p = 0.16; Figure 5), even when we excluded the
trial comparison A27 OLCSG1b (data not shown; interaction p
= 0.07).
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Figure 5. Exploratory analyses of the effect of surgery (S) and chemotherapy (CT) versus surgery on
survival, by the use of tegafur plus uracil/tegafur.
We recorded no significant evidence (p ≥ 0.10) that any patient
subgroup defined by age, sex, histology, performance status, or
stage benefited more or less from adjuvant chemotherapy (Figure
6). However, because of the geographical differences in the types
of patients and chemotherapy used, we undertook exploratory
subgroup analyses separately for trial comparisons using platinum,
without tegafur plus uracil or tegafur alone, and those using these
drugs. We split stage I disease into IA and IB for all but five trial
comparisons (A04 Park1; A19SGACLCACTLC1;A21SGACLC
ACTLC2; A26 OLCSG2b; A32 OLCSG2a) which we had to
exclude since this information was not available.
13Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 6. The effect of surgery (S) and chemotherapy (CT) versus surgery on survival by patient subgroup.
For the platinum without tegafur plus uracil or tegafur alone
group, although there was no evidence of difference in the effect
of adjuvant chemotherapy between patients with good and poor
performance status (interaction p = 0.30; Figure 7), we noted an
increasing relative effect of adjuvant chemotherapy with improv-
ing performance status (trend p = 0.002; Figure 7), which was
consistent across trials (data not shown; p = 0.32). However, a
few patients had a poor performance status (Figure 7). The rela-
tive effect of adjuvant chemotherapy did not differ significantly by
other patient subgroups, including stage (trend p = 0.13; Figure
7). Therefore, application of the overall hazard ratio to survival in
the control group by stage suggests absolute improvements in 5-
year survival of 3% (95% CI 2 to 5) for stage IA (from 70% to
73%), 5% (2 to 7) for stage IB (from 55% to 60%), 5% (3 to
8) for stage II (from 40% to 45%), and 5% (3 to 8) for stage III
disease (from 30% to 35%). The suggested survival benefit of 3%
for stage IA and the hazard ratio of 1.19 (95% CI 0.84 to 1.68)
for that subgroup seemed to be contradictory. However, data are
scarce for this group of patients, the CIs are very wide, and the
result is not significant (p = 0.33).
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Figure 7. Exploratory analyses of the effect of surgery (S) and chemotherapy (CT) versus surgery on
survival, by use of tegafur plus uracil or tegafur and by stage and performance status.
In the tegafur and uracil or tegafur alone group, we noted no clear
difference in the effect of adjuvant chemotherapy between patients
with good or poor performance status (interaction p = 0.49; Figure
7), but did record a suggestion of an increasing relative effect of
adjuvant chemotherapywith worsening performance status (trend
p=0.02; Figure 7). This trend varies substantially across trials (data
not shown; p = 0.01), and few patients had a poor performance
status. We noted no significant difference in the relative effect
of adjuvant chemotherapy by age, sex, histology, or stage, and
application of the overall HR gave absolute improvements in 5-
year survival of 2% (95% CI 1 to 3) for stage IA (from 80% to
82%), 3% (1 to 4) for stage IB (from 75% to 78%), 5% (2 to
7) for stage II (from 45% to 50%), and 5% (3 to 8) for stage III
disease (from 25% to 30%).
Data for recurrence-free survival were available for 18 trial com-
parisons (2519 events; 5379 patients) and data for locoregional
(936 events; 5226 patients) and distant recurrence (1267 events;
5224 patients) for 16 trial comparisons, mostly from newer trials
of platinum-based chemotherapy without tegafur plus uracil or
tegafur alone. Results for recurrence-free survival (HR 0.83, 95%
CI 0.77 to 0.90, p < 0.0001), time to locoregional recurrence (HR
0.75, 95%CI 0.66 to 0.85, p < 0.0001), and time to distant recur-
rence (HR 0.80, 95%CI 0.72 to 0.89, p = 0.0007) all significantly
favoured adjuvant chemotherapy. Exclusion of the four trial com-
parisons that included tegafur plus uracil or tegafur alone (A23
WJSG3; A24 Xu; A33 ACTLC4b; A34 JLCRG) showed similar
results (data not shown).
Surgery plus radiotherapy versus surgery plus radiotherapy
plus adjuvant chemotherapy
Overall survival analyses were based on 12 trial comparisons and
2660 patients (1909 deaths), representing 86% of patients who
were randomly assigned. The results (Analysis 2.1) showed a clear
benefit of adjuvant chemotherapy (HR0.88, 95%CI 0.81 to 0.97,
p = 0.009; Figure 8), with little heterogeneity (p = 0.95, I² = 0%).
This finding represents an absolute benefit of 4% (95% CI 1 to
8) at 5 years, increasing survival from 29% to 33% (Figure 4).
We recorded no evidence of a differential effect by chemotherapy
category (interaction p = 0.45; Figure 8) or the extent of resection
achieved: trials with complete resection only (6 trials, 2005 pa-
tients; HR 0.87, 95% CI 0.78 to 0.97) versus trials with complete
or incomplete resection (6 trials, 655 patients; HR 0.92, 95% CI
0.78 to 1.08); interaction p = 0.63. Furthermore, an exploratory
analysis suggests that the timing of chemotherapy in relation to
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radiotherapy is unimportant: trials with chemotherapy before ra-
diotherapy (9 trials, 1928 patients; HR 0.86, 95% CI 0.77 to
0.96) versus trials with concomitant chemoradiotherapy (3 trials,
732 patients; HR 0.95, 95% CI 0.81 to 1.12); interaction p =
0.30.
Figure 8. Forest plot of comparison: 2 surgery + radiotherapy versus surgery + radiotherapy +
chemotherapy, outcome: 2.1 Survival.
The relative effect of adjuvant chemotherapy did not differ signif-
icantly by age, sex, histology, performance status, or stage (Figure
9). Data for recurrence-free survival, and locoregional and dis-
tant recurrence were available for eight trial comparisons (2247
patients). Results for recurrence-free survival (1673 events, 2247
patients; HR 0.85, 95% CI 0.77 to 0.93, p = 0.0006), time to
locoregional recurrence (533 events; HR 0.79, 95% CI 0.67 to
0.94, p = 0.008), and time to distant recurrence (806 events; HR
0.75, 95% CI 0.66 to 0.87, p < 0.0001) all showed a significant
benefit of adjuvant chemotherapy.
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Figure 9. The effect of surgery (S) and radiotherapy (RT) and chemotherapy (CT) versus surgery and
radiotherapy on survival by patient subgroup.
D I S C U S S I O N
Summary of main results
Our results show a benefit of adjuvant chemotherapy after surgery,
which has been already shown in some large trials but not in others
(for example, A06ALPI1 and A14CALGB 9633). They also show
a benefit of chemotherapy in the presence of postoperative radio-
therapy. The absolute survival improvements of 4%at five years are
fairly modest, but might result in 10,000 to 16,000 more patients
alive at five years (Datta 2003). The results of the two meta-analy-
ses are based on data from 47 comparisons in 33 trials and 11,107
patients with non-small cell lung cancer (NSCLC), which is more
than three times that available in theNSCLCCollaborative Group
1995. In these meta-analyses, we have an opportunity to bring
together most trials undertaken during the past few decades, and
to assess the effectiveness of adjuvant chemotherapy in patients
with NSCLC worldwide.
Although we noted no significant difference in effect between che-
motherapy categories in the first meta-analysis, results for the trials
that used older vinca alkaloids (vinblastine, vindesine, vincristine),
etoposide, or other platinum combinations were somewhat uncer-
tain, whereas trials using a combination of platinum and vinorel-
bine provided slightly more reliable evidence of benefit to inform
present clinical practice (Figure 1; Figure 8). The results for che-
motherapy with tegafur plus uracil or tegafur alone are similar to
those for platinum-based regimens. However, results come largely
from older studies in Asian populations, which are increasingly
showing differences in their response to treatment (Sekine 2008),
and so cannot be extrapolated to modern practice in non-Asian
patients. A trial of tegafur plus uracil or tegafur alone in patients
with stage IA, adenocarcinoma from non-Asian countries would
be beneficial in this context. Results of an ongoing trial might
establish the relative merits of carboplatin-paclitaxel and tegafur
plus uracil in Asian patients (Toyooka 2009).
Guidelines from Cancer Care Ontario and American Society of
Clinical Oncology (ASCO) (Pisters 2007) recommend that adju-
vant cisplatin-based chemotherapy is given to patients with stage
II and IIIA NSCLC.
These guidelines state that evidence is insufficient to make rec-
ommendations for patients with stage IA disease, and one meta-
analysis (Pignon 2008) reported a significant decrease in the effect
of adjuvant cisplatin-based chemotherapy by stage, largely driven
by the stage IA result. This meta-analysis does not show signifi-
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cant differences in the effect of platinum chemotherapy (without
tegafur plus uracil or tegafur alone) by stage or significantly poorer
survival in patients with stage IA disease (Figure 7). The evidence
in stage IA tumours remains scarce until results from further trials
are available.
The ASCO guidelines also state that none of the studies reviewed
showed a significant benefit of adjuvant chemotherapy in patients
with stage IB tumours. By contrast, our estimate of the effect of
platinum-based adjuvant chemotherapy in patients with stage IB
tumours is based on a substantial number of events and is simi-
lar to estimates for patients with stage II and III tumours (Figure
7). Since we did not collect data for tumour size, patients with
larger stage IB tumours, who would be classed as stage II in the
7th edition of the TNM staging system (IASLC 2009) and might
achieve a greater benefit from adjuvant chemotherapy are poten-
tially included. In the absence of comorbidities and contraindica-
tions to chemotherapy, our findings show that adjuvant platinum-
based chemotherapy may be considered as a treatment option for
patients at high risk of recurrence, ie, those with stage IB, II, or III
disease. Whethercisplatin-based chemotherapy should be used in
patients with stage IA disease remains uncertain, since the scarcity
of data did not allow us to distinguish reliably between a benefit,
a detriment, or no effect. Most patients had good performance
status and the benefit was clear in this group. A small increasing
effect of platinum-based chemotherapy with better performance
status was also apparent in this and another meta-analysis (Pignon
2008), but was not confirmed in trials using tegafur plus uracil or
tegafur alone, or those that included postoperative radiotherapy.
Nevertheless, these results could suggest cautious use of platinum-
based chemotherapy in less fit patients. Despite the amount of
data collected, some of the subgroup analyses lacked power.
The benefits of adjuvant chemotherapy have been reported to
be attenuated in long-term results (Arriagada 2010; Butts 2010),
however, we do not have much data beyond five years. The poten-
tial benefit of adjuvant chemotherapy should always be balanced
with possible toxic effects for the individual patient. We were un-
able to assess toxic effects of treatment in this study. Moreover,
extrapolation of the results to patients with comorbidities is un-
certain because most of the patients included in these meta-anal-
yses had mild or no comorbidities. Quality of life was measured
in only a few trials and so could not be reviewed.
Overall completeness and applicability of
evidence
Surgery versus surgery plus adjuvant chemotherapy
We identified 35 eligible trials and included 26. We could not
include nine trials; five could not be included as data were not
available; two could not be included as adequate contact could
not be made with the trial investigators; and two were published
too recently to be included (but will be included in a subsequent
update). Therefore this represents 92% of all patients who were
randomised into eligible trials.
Surgery plus radiotherapy versus surgery plus
radiotherapy plus adjuvant chemotherapy
We identified 15 eligible trials and included 12. We could not
include three trials; one could not be included as data were not
available; and two could not be included as adequate contact could
not be made with the trial investigators. Therefore this represents
86% of all patients who were randomised into eligible trials.
Quality of the evidence
The trials included in this update show an overall low risk of
bias in the domains we considered to be most important; those
being adequate sequence generation and allocation concealment.
Blinding was not appropriate due to the nature of the treatments
and any issues surrounding the reporting of incomplete outcome
data, selective outcome reporting or attrition bias were overcome
by the collection of individual participant data. We are confident
that further research is unlikely to change the findings. The studies
were well designed and conducted, address the review question
and the effects are consistent across trials. The impact of any data
we have not been able to include in our analyses is small.
Potential biases in the review process
We aimed to include all trials, unpublished and unpublished, re-
gardless of the language they were published in. We collected
IPD for all included trials. The first meta-analysis (surgery ver-
sus surgery plus adjuvant chemotherapy) included 92% of eligi-
ble data and the second meta-analysis (surgery plus radiotherapy
versus surgery plus radiotherapy plus adjuvant chemotherapy) in-
cluded 86% of eligible data. Had we been able to include this extra
data, it is unlikely they would have had an impact on these results.
We checked and verified data against the published results. We
resolved any queries and verified the final database by each trial
investigator or statistician. We deemed all included trials to have
a low risk of bias using the ’Risk of bias’ tool.
Agreements and disagreements with other
studies or reviews
This is an update and extension of a previous systematic review
and meta-analysis. The results are still in favour of the addition of
chemotherapy to surgery and postoperative radiotherapy, however
these results are more up to date and contain more than three
times more patients than that available in 1995.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The addition of chemotherapy following surgery and postopera-
tive radiotherapy gave a 4% improvement in 5-year survival from
29% to 33%. This benefit should be balanced against possible
toxicity and quality of life. Where toxicity was assessed and men-
tioned in the publications, it was thought to be manageable. This
4% increase does not seem to vary with the timing of chemother-
apy in relation to radiotherapy, extent of surgery, or by patient
subgroup (Figure 6; Figure 9). The lower survival rates than those
in the surgery and chemotherapy meta-analysis are most likely be-
cause patients with stage III tumours predominate and the incom-
plete resection rate is higher (Table 2). A previous meta-analysis
(PORT 1998; PORT 2005) has shown that postoperative radio-
therapy has a detrimental effect on survival, particularly for early
stage tumours, but old radiotherapy techniques were used.
Implications for research
This meta-analysis was not designed to study the effect of post-
operative radiotherapy, but has shown that the effect of chemo-
therapy is similar, irrespective of what locoregional treatment is
used: surgery alone or surgery plus postoperative radiotherapy.
Randomised trials are needed to assess whether modern radiother-
apy is effective as an adjuvant treatment. Since this review was
completed, we have found further eligible trials (NATCH 2010;
Wang 2009; Zheng 2011); (see Characteristics of studies awaiting
classification and Characteristics of excluded studies) it is hoped
that we will be able to include these trials in a future update of
this project.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
A01 IPCR, Chiba
Methods RCT: 1985 to 1991
Participants 29 patients
Stage NK
Interventions surgery vs surgery + chemotherapy
cisplatin 80 mg/m2
vindesine 3 mg/m2
mitomycin c 8 mg/m2
Complete and incomplete resection
Outcomes Overall survival
Notes > 2 cycles of chemotherapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Sealed envelope
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A02 JLCSSG
Methods RCT: 1986 to 1988
Participants 209 patients
Stage III
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A02 JLCSSG (Continued)
Interventions surgery vs surgery + chemotherapy
2-3 cycles of chemotherapy
cisplatin 80 mg/m2
vindesine 6 mg/m2
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Permuted block randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A03 Mineo
Methods RCT: 1988 to 1994
Participants 66 patients
Stage IB
Interventions surgery vs surgery + chemotherapy
6 cycles of chemotherapy
cisplatin 100 mg/m2etoposide 120 mg/m2
Complete resection
Outcomes Overall survival
5 year recurrence-free survival
Recurrence rates
Cause of death
Notes 140 patients in trial, only 66 reported at time of data collection, therefore only 66 patients
included
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A03 Mineo (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central computer randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A04 Park1
Methods RCT: 1989 to 1998
Participants 118 patients
Stage I
Interventions surgery vs surgery + chemotherapy
3-4 cycles of chemotherapy
mitomycin c 10mg/m2
vinblastin 6 mg/m2
cisplatin 100 mg/m2
Complete resection
Outcomes Overall survival
Recurrence-free survival
Death from any cause
Toxicity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
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A04 Park1 (Continued)
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A05 Park2
Methods RCT: 1989 to 1998
Participants 108 patients
Stage IIIA
Interventions surgery vs surgery + chemotherapy
3-4 cycles of chemotherapy
cisplatin 100 mg/m2
mitomycin c 10 mg/m2
vinblastine 6 mg/m2
Complete resection
Outcomes Overall survival
Recurrence-free survival
Notes 2 arms of a 3-arm trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
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A06 ALPI1
Methods RCT: 1994 to 1999
Participants 618 patients
Stage I-IIIA
Interventions surgery vs surgery + chemotherapy
3 cycles of chemotherapy
cisplatin 100 mg/m2
vindesine 6 mg/m2
mitomycin 8 mg/m2
Complete resection
Outcomes Overall survival
Recurrence-free survival
Toxicity
Notes 1088 patients analysed, 470 received RT, only 618 patients relevant to this trial compar-
ison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A07 IALT1
Methods RCT: 1995 to 2001
Participants 1001 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
3 or 4 cycles of chemotherapy
cisplatin 80, 100 or 120 mg/m2
and vindesine 3 mg/m2
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A07 IALT1 (Continued)
or vinblastine 8 mg/m2
or etoposide 300 mg/m2
Complete resection
Outcomes Overall survival
Recurrence-free survival
Causes of death
Notes 1867 patients randomised to trial, 1001 patients in this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A08 BLT1
Methods RCT: 1995 to 2001
Participants 136 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
3 cycles of chemotherapy
cisplatin 50 mg/m2
mitomycin 6 mg/m2
vinblastine 6 mg/m2
or
cisplatin 80
vindestine 6
Complete resection
Outcomes Overall survival
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A08 BLT1 (Continued)
Notes 381 patients randomised in surgical setting, 136 relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A09 JCOG 9304
Methods RCT: 1994 to 1999
Participants 119 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
3 cycles of chemotherapy
cisplatin 80 mg/m2
vindesine 3 mg/m2
Complete and incomplete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Randomisation by blocks within each institution
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A09 JCOG 9304 (Continued)
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A10 ANITA1
Methods RCT: 1994 to 2000
Participants 463 patients
Stage IB-IIIA
Interventions surgery vs surgery + chemotherapy
4 cycles of chemotherapy
cisplatin 100 mg/m2
vinorelbine 180 mg/m2
Complete resection
Outcomes Overall survival
Notes 840 patients randomised in trial, 436 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central computer randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
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A11 JBR10
Methods RCT: 1994 to 2001
Participants 482 patients
Stage IB-II
Interventions surgery vs surgery + chemotherapy
4 cycles of chemotherapy
cisplatin 50 mg/m2
vinorelbine 25mg/m2 (initial patients received 30 mg/m2 )
Complete resection
Outcomes Overall survival
Recurrence-free survival
Notes Updated survival published in 2010, data included here is as published in 2005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A12 IALT2
Methods RCT 1995 to 2001
Participants 294 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
3 or 4 cycles of chemotherapy
cisplatin 80, 100 or 120 mg/m2
vinorelbine 30 mg/m2
Complete resection
34Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A12 IALT2 (Continued)
Outcomes Overall survival
Recurrence-free survival
Causes of death
Notes 1867 patients randomised to trial, 294 patients in this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A13 BLT2
Methods RCT 1995 to 2001
Participants 65 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
3 cycles of chemotherapy
cisplatin 80 mg/m2
vinorelbine 60 mg/m2
Complete resection
Outcomes Overall survival
Notes 381 patients randomised in surgical setting, 65 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
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A13 BLT2 (Continued)
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A14 CALGB 9633
Methods RCT: 1996 to 2003
Participants 344 patients
Stage IB
Interventions surgery vs surgery + chemotherapy
4 cycles of chemotherapy
carboplatin 6mg/mL over 45-60 min
vinorelbine 30 mg/m2
Complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
36Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A15 LCSG 801
Methods RCT: 1980 to 1986
Participants 283 patients
Stage I
Interventions surgery vs surgery + chemotherapy
4 cycles of chemotherapy
cisplatin 60 mg/m2
doxorubincin 40 mg/m2
cyclophosphamide 400 mg/m2
Complete resection
Outcomes Overall survival
Notes 4 cycles of chemotherapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk N/A IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A16 FLCSG 1
Methods RCT: 1982 to 1987
Participants 110 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
6 cycles of chemotherapy
cisplatin 40 mg/m2
doxorubicin 40 mg/m2
cyclophosphamide 400 mg/m2
Outcomes Overall survival
37Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A16 FLCSG 1 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A17 LCSG 853
Methods RCT: 1985 to 89
Participants 188 patients
Stage II-III
Interventions surgery vs surgery + chemotherapy
4 cycles of chemotherapy
cisplatin 60 mg/m2
doxorubicin 40 mg/m2
cyclophosphamide 400 mg/m2
Complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
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A17 LCSG 853 (Continued)
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A18 BLT3
Methods RCT: 1995 to 2001
Participants 118 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
3 cycles of chemotherapy
cisplatin 50 mg/m2
mitomycin 6 mg/m2
ifosphamide 3 mg/m2
Complete resection
Outcomes Overall survival
Notes 381 patients randomised in surgical setting, 118 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
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A19 SGACLC ACTLC1
Methods RCT: 1982 to 1985
Participants 306 patients
Stage NK
Interventions surgery vs surgery + chemotherapy
10 cycles of chemotherapy
cisplatin 0.08 mg/kg
mitomycin 2 mg/kg
tegafur 12 mg/kg daily treatment > 6 months
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A20 OLCSG1c
Methods RCT: 1982 to 1987
Participants 28 patients
Stage II
Interventions surgery vs surgery + chemotherapy
1 cycles of chemotherapy
cisplatin 80 mg/m2
tegafur 600-800 mg/m2, daily treatment > 1 year
Complete resection
Outcomes Overall survival
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A20 OLCSG1c (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A21 SGACLC ACTLC2
Methods RCT: 1985 to 1987
Participants 332 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
cisplatin 66 mg/m2
doxorubicin 26 mg/m2
UFT 8 mg/kg, daily treatment > 6 months
Complete and incomplete resection
Outcomes Overall survival
Notes Unpublished
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Sealed envelope
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
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A21 SGACLC ACTLC2 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A22 WJSG 2 (1+3)
Methods RCT:1985 to 1988
Participants 323 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
1 cycle of chemotherapy
cisplatin 50mg/m2
vindesine 6-9mg/m2
UFT 400mg/m2 , daily treatment 1 year
Complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
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A23 WJSG3
Methods RCT: 1988 to 1989
Participants 225 patients
Stage I-II
Interventions surgery vs surgery + chemotherapy
2 cycles of chemotherapy
cisplatin 80 mg/m2
vindesine 2-3 mg/m2
mitomycin 8 mg/m2
tegafur and uracil 400 mg/m2 (total), daily treatment for 1 year
Complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A24 Xu
Methods RCT: 1989 to 1992
Participants 70 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
4 cycles of chemotherapy
cisplatin 100 mg/m2
cyclophosphamide 300 mg/m2
vincristine 1.4 mg/m2
doxorubicin 50 mg/m2
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A24 Xu (Continued)
lomustine 50 mg/m2
oral tegaful 600-900 mg/m2 (total), daily treatment for 1 year
Complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Sealed envelope
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A25 ACTLC4a
Methods RCT: 1982 to 1988
Participants 104 patients
Stage I
Interventions surgery vs surgery + chemotherapy
cisplatin 80 mg/m2, 1 cycle
vindesine 6 mg/m2 , 2 cycles
tegafur and uracil 400 mg/m2 (total), daily treatment for 2 years
Complete resection
Outcomes Overall survival
Recurrence-free survival
Toxicity
Notes 156 patients randomised in trial, 104 patients relevant to this trial comparison
Risk of bias
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A25 ACTLC4a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A26 OLCSG2b
Methods RCT: 1992 to 1994
Participants 95 patients
Stage II-III
Interventions surgery vs surgery + chemotherapy
2 cycles of chemotherapy
cisplatin 80 mg/m2
vindesine 6 mg/m2
tegafur and uracil 400 mg/m2 (total), daily treatment for 1 year
Complete resection
Outcomes Overall survival
Notes 267 patients randomised in trial, 95 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
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A26 OLCSG2b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A27 OLCSG1b
Methods RCT: 1982 to 1986
Participants 83 patients
Stage II-III
Interventions surgery vs surgery + chemotherapy
3 cycles of chemotherapy
doxorubicin 100 mg/m2
mitomycin 20 mg/m2
tegafur 600-800 mg/m2, daily treatment
followed by tegafur 600-800 mg/m2 daily treatment > 1 year
Complete and incomplete resection
Outcomes Overall survival
Recurrence-free interval
Notes 363 patients randomised in trial, 83 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
46Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A28 OLCSG1a
Methods RCT: 1982 to 1987
Participants 321 patients
Stage I
Interventions surgery vs surgery + chemotherapy
tegafur 600-800 mg/m2 , daily treatment > 1 year
Complete resection
Outcomes Overall survival
Recurrence-free interval
Notes 363 patients randomised in trial, 321 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A29 WJSG2 (2+3)
Methods RCT: 1985 to 1988
Participants 208 patients
Stage I-III
Interventions surgery vs surgery + chemotherapy
tegafur and uracil 400mg/m2 , daily treatment for 1 year
Complete resection
Outcomes Overall survival
Notes 323 patients randomised in trial, 208 patients relevant to this comparison
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A29 WJSG2 (2+3) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A30 WJSG4
Methods RCT: 1991 to 1994
Participants 367 patients
Stage I-II
Interventions surgery vs surgery + chemotherapy
tegafur and uracil 400 mg/m2 (total), daily treatment for 1 year
Complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
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A30 WJSG4 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A31 NJSGLCS
Methods RCT: 1992 to 1994
Participants 219 patients
Stage I-II
Interventions surgery vs surgery + chemotherapy
tegafur and uracil 260 mg/m2 total or 400 mg/m2 total, daily treatment for 2 years
Complete resection
Outcomes Overall survival
Recurrence-free survival
Toxicity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A32 OLCSG2a
Methods RCT: 1992 to 1994
Participants 172 patients
Stage I
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A32 OLCSG2a (Continued)
Interventions surgery vs surgery + chemotherapy
tegafur and uracil 400 mg/m2 (total), daily treatment for 1 year
Complete resection
Outcomes Overall survival
Recurrence-free survival
Notes 267 patients randomised in trial, 172 relevant to this comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A33 ACTLC4b
Methods RCT: 1992 to 1995
Participants 104 patients
Stage I
Interventions surgery vs surgery + chemotherapy
tegafur and uracil 400 mg/m2 (total), daily treatment for 2 years
Complete resection
Outcomes Overall survival
Recurrence-free survival
Safety
Notes 156 patients randomised in trial, 104 relevant to this comparison
Risk of bias
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A33 ACTLC4b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
A34 JLCRG
Methods RCT: 1994 to 1997
Participants 999 patients
Stage I
Interventions surgery vs surgery + chemotherapy
tegafur and uracil 250 mg/m2 (total), daily treatment for 2 years
Complete and incomplete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
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A34 JLCRG (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
B01 MSKCC 80-53
Methods RCT: 1981 to 1987
Participants 72 patients
Stage III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 120mg/m2
vindesine 9 mg/m2
4 cycles of chemotherapy
radiotherapy 46 Gy
complete and incomplete resections
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Not reported (unpublished)
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
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B02 GETCB 01CB82
Methods RCT: 1982 to 1986
Participants 267 patients
Stage I-III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
doxorubicin 40 mg/m2
vincristine 1.2 mg/m2
cisplatin 75 mg/m2
lomustine 80 mg/m2(total) alternating with cyclophosphamide 600 mg/m2
3 cycles of chemotherapy given before radiotherapy
radiotherapy 60-65 Gy in 30-33 fractions
complete and incomplete resection
Outcomes Overall survival
Recurrence-free survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for all outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B03 EORTC 08861
Methods RCT: 1986 to 1990
Participants 22 patients
Stage IIB-IIIA
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 100 mg/m2
vindesine 6 mg/m2
4 cycles of chemotherapy, 2 given before radiotherapy
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B03 EORTC 08861 (Continued)
radiotherapy 56 Gy in 28 fractions
complete resection
Outcomes Overall survival
Notes unpublished
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for all outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B04 MDA DM 87045
Methods RCT: 1987 to 1993
Participants 34 patients
Stage NK
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 50-100 mg/m2
etoposide 60-120 mg/m2
cyclophosphamide 300-600 mg/m2
CT given before RT, number of cycles unknown
radiotherapy 50-60 Gy in 25-33 fractions
incomplete resection
Outcomes Overall survival
Recurrence-free survival
Notes Unpublished
Risk of bias
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B04 MDA DM 87045 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B05 INT 0115
Methods RCT: 1991 to 1997
Participants 488 patients
Stage II-IIIA
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 60 mg/m2
etoposide 360 mg/m2
4 cycles of chemotherapy given concomitantly with radiotherapy
radiotherapy 56 Gy in 28 fractions
complete resection
Outcomes Overall survival
Recurrence-free survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
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B05 INT 0115 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B06 ALPI2
Methods RCT 1994-99
Participants 470 patients
Stage I-IIIA
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 100 mg/m2
vindesine 6 mg/m2
mitomycin c 8 mg/m2
3 cycles of chemotherapy given before radiotherapy
radiotherapy 50-54 Gy in 25-27 fractions
complete resection
Outcomes Overall survival
Recurrence-free survival
Toxicity
Notes 1088 patients analysed, 470 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
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B07 IALT3
Methods RCT: 1995 to 2001
Participants 1001 patients
Stage I-III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin (80, 100 or 120 mg/m2) and vindesine 3 mg/m2
or
vinblastine 8 mg/m2
or
etoposide 300 mg/m2
3 or 4 cycles of chemotherapy given before radiotherapy
radiotherapy < 60 Gy
complete resection
Outcomes Overall survival
Recurrence-free survival
Causes of death
Notes 1867 patients randomised to trial, 366 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B08 BLT4
Methods RCT: 1995 to 2001
Participants 49 patients
Stage I-III
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B08 BLT4 (Continued)
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin (80, 100 or 120mg/m2 ) and vindesine
mitomycin c 8 mg/m2
3 cycles of chemotherapy given before radiotherapy
radiotherapy < 60 Gy
complete resection
Outcomes Overall survival
Recurrence-free survival
Notes 381 patients randomised to trial, 49 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B09 ANITA2
Methods RCT: 1994 to 2000
Participants 377 patients
Stage IB-IIIA
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 100 mg/m2
vinorelbine 120 mg/m2
4 cycles of chemotherapy given before radiotherapy
radiotherapy 45-60 Gy in 23-30 fractions
complete resection
Outcomes Overall survival
Recurrence-free survival
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B09 ANITA2 (Continued)
Notes 840 patients randomised in trial, 377 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
B10 IALT4
Methods RCT: 1994 to 2001
Participants 206 patients
Stage I-III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin (80, 100 or 120mg/m2 )
vinorelbine 30 mg/m2
3 or 4 cycles of chemotherapy given before radiotherapy
radiotherapy < 60 Gy
complete resection
Outcomes Overall survival
Recurrence-free survival
Causes of death
Notes 1867 patients randomised in trial, 206 patients relevant to this trial comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
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B10 IALT4 (Continued)
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
B11 LCSG 791
Methods RCT: 1979 to 85
Participants 172 patients
Stage I-III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cyclophosphamide 400 mg/m2
doxorubicin 40 mg/m2
cisplatin 40 mg/m2
6 cycles of chemotherapy, concomitant chemotherapy-radiotherapy for 1st 2 cycles of
chemotherapy
radiotherapy 40 Gy in 10 fractions
incomplete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Central randomisation
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
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B11 LCSG 791 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
B12 FLCSG 3
Methods RCT: 1982 to 1987
Participants 86 patients
Stage I-III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cyclophoshamide 400 mg/m2
doxorubicin 40 mg/m2
cisplatin 40 mg/m2
8 cycles of chemotherapy, 2 given before radiotherapy
radiotherapy 55 Gy in 20 fractions
incomplete resection
Outcomes Overall survival
Notes unpublished
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Sealed envelope
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
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B13 OLCSG1d
Methods RCT: 1983 to 1987
Participants 49 patients
Stage III
Interventions surgery + radiotherapy vs surgery + radiotherapy + chemotherapy
cisplatin 80 mg/m2(given once)
tegafur* 600-800 mg/m2 (daily treatment)
chemotherapy before radiotherapy, unknown number of cycles of chemotherapy
radiotherapy 40 Gy in 20 fractions
complete resection
Outcomes Overall survival
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Data checks on IPD provided suggest adequate sequence gener-
ation
Allocation concealment (selection bias) Low risk Sealed envelope
Selective reporting (reporting bias) Low risk IPD supplied for outcomes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial not blinded due to nature of intervention, outcome not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial not blindeddue tonature of intervention, primary outcome
not likely to be influenced by lack of blinding
Gy - Gray, unit of radiotherapy dose
IPD - Individual participant data
NK - not known
N/A - not available
UFT - Uracil/tegafur
RCT - randomised controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ayoub 1991 Data not available
Clerici 1991 Data not available
EORTC 08922 Data not available
Ichinose 1991 Data not available
Kim 2003 No contact with trialist established
NCCTG 852451 Data not available
Ueda 2004 No contact with trialist established
Wang 2009 Trial discovered too late to be included in this analysis
Wolf 2001 No contact with trialist established
Wu 2009 Trial discovered too late to be included in this analysis
Zarogoulidis 1996 No contact with trialist established
Characteristics of studies awaiting assessment [ordered by study ID]
NATCH 2010
Methods Randomised controlled trial
Participants 423 patients relevant
Interventions Surgery + chemotherapy vs surgery
Outcomes Recurrence-free survival
Notes
Zheng 2011
Methods Randomised controlled trial
Participants 70 patients
Interventions Surgery + chemotherapy vs surgery
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Zheng 2011 (Continued)
Outcomes Overall survival
Notes
Characteristics of ongoing studies [ordered by study ID]
CALGB 30506
Trial name or title CALGB 30506: Phase III randomised study of adjuvant chemotherapy versus observation in patients with
early stage non-small cell lung cancer
Methods Randomised controlled trial
Participants 1620 patients planned
Interventions Surgery + chemotherapy vs surgery
Outcomes Overall survival
Starting date March 2009
Contact information Protocol Chair: David Harpole MD
Notes Estimated completion date, Jan 2014
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D A T A A N D A N A L Y S E S
Comparison 1. Surgery versus surgery + adjuvant chemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 34 Hazard Ratio (95% CI) Subtotals only
1.1 Platinum + vinca
alkaloid/etoposide
9 2404 Hazard Ratio (95% CI) 0.94 [0.84, 1.05]
1.2 Platinum + vinorelbine 4 1304 Hazard Ratio (95% CI) 0.82 [0.70, 0.97]
1.3 Platinum + taxane 1 344 Hazard Ratio (95% CI) 0.77 [0.57, 1.05]
1.4 Other platinum regimens 4 699 Hazard Ratio (95% CI) 0.90 [0.72, 1.13]
1.5 Platinum + vinca alkaloid
+ tegafur and uracil/tegafur
8 1375 Hazard Ratio (95% CI) 0.79 [0.67, 0.93]
1.6 Tegafur and uracil/tegafur
+ other agent
1 83 Hazard Ratio (95% CI) 1.79 [1.00, 3.20]
1.7 Tegafur and uracil/tegafur 7 2390 Hazard Ratio (95% CI) 0.76 [0.64, 0.90]
Comparison 2. Surgery + radiotherapy versus surgery + radiotherapy + adjuvant chemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 13 2660 Hazard Ratio (95% CI) 0.88 [0.81, 0.97]
1.1 Platinum + vinca
alkaloid/etoposide
8 1770 Hazard Ratio (95% CI) 0.93 [0.83, 1.03]
1.2 Platinum + vinorelbine 2 583 Hazard Ratio (95% CI) 0.77 [0.63, 0.94]
1.3 Other platinum regimen 2 258 Hazard Ratio (95% CI) 0.85 [0.65, 1.11]
1.4 Antimetabolic agent only 1 49 Hazard Ratio (95% CI) 1.02 [0.45, 2.34]
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Analysis 1.1. Comparison 1 Surgery versus surgery + adjuvant chemotherapy, Outcome 1 Survival.
Review: Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
Comparison: 1 Surgery versus surgery + adjuvant chemotherapy
Outcome: 1 Survival
Study or subgroup Treatment Control Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Platinum + vinca alkaloid/etoposide
A01 IPCR, Chiba 11/15 7/14 1.4 % 1.39 [ 0.52, 3.66 ]
A02 JLCSSG 59/111 52/98 9.3 % 1.04 [ 0.71, 1.51 ]
A03 Mineo 14/33 21/33 2.9 % 0.51 [ 0.26, 0.99 ]
A04 Park1 17/59 23/59 3.4 % 0.66 [ 0.35, 1.23 ]
A05 Park2 37/53 43/55 6.8 % 0.81 [ 0.52, 1.26 ]
A06 ALPI1 143/310 144/308 24.3 % 1.01 [ 0.80, 1.28 ]
A07 IALT1 235/499 243/502 40.6 % 0.94 [ 0.78, 1.12 ]
A08 BLT1 34/69 32/67 5.6 % 1.03 [ 0.64, 1.68 ]
A09 JCOG 9304 33/59 35/60 5.8 % 0.97 [ 0.61, 1.57 ]
Subtotal (95% CI) 1208 1196 100.0 % 0.94 [ 0.84, 1.05 ]
Heterogeneity: Chi2 = 6.35, df = 8 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
2 Platinum + vinorelbine
A10 ANITA1 102/231 113/232 38.7 % 0.94 [ 0.72, 1.23 ]
A11 JBR10 86/242 111/240 35.4 % 0.71 [ 0.54, 0.94 ]
A12 IALT2 55/149 61/145 20.9 % 0.87 [ 0.60, 1.25 ]
A13 BLT2 15/37 15/28 5.1 % 0.64 [ 0.31, 1.34 ]
Subtotal (95% CI) 659 645 100.0 % 0.82 [ 0.70, 0.97 ]
Heterogeneity: Chi2 = 2.49, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.021)
3 Platinum + taxane
A14 CALGB 9633 78/173 93/171 100.0 % 0.77 [ 0.57, 1.05 ]
Subtotal (95% CI) 173 171 100.0 % 0.77 [ 0.57, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
4 Other platinum regimens
A15 LCSG 801 66/140 71/143 43.8 % 0.95 [ 0.68, 1.33 ]
A16 FLCSG 1 20/54 30/56 15.6 % 0.53 [ 0.30, 0.93 ]
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
A17 LCSG 853 29/94 32/94 19.5 % 0.90 [ 0.54, 1.48 ]
A18 BLT3 34/56 34/62 21.0 % 1.22 [ 0.75, 1.97 ]
Subtotal (95% CI) 344 355 100.0 % 0.90 [ 0.72, 1.13 ]
Heterogeneity: Chi2 = 5.04, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 0.91 (P = 0.36)
5 Platinum + vinca alkaloid + tegafur and uracil/tegafur
A19 SGACLC ACTLC1 68/154 75/152 24.9 % 0.82 [ 0.59, 1.14 ]
A20 OLCSG1c 5/12 7/16 2.0 % 0.94 [ 0.30, 2.95 ]
A21 SGACLC ACTLC2 64/165 68/167 23.0 % 0.86 [ 0.61, 1.22 ]
A22 WJSG 2 (1+3) 44/115 49/100 16.0 % 0.72 [ 0.48, 1.08 ]
A23 WJSG3 27/109 40/116 11.7 % 0.70 [ 0.43, 1.13 ]
A24 Xu 19/35 26/35 7.8 % 0.66 [ 0.37, 1.18 ]
A25 ACTLC4a 10/52 18/52 4.8 % 0.47 [ 0.22, 0.99 ]
A26 OLCSG2b 28/47 28/48 9.7 % 1.19 [ 0.70, 2.01 ]
Subtotal (95% CI) 689 686 100.0 % 0.79 [ 0.67, 0.93 ]
Heterogeneity: Chi2 = 5.40, df = 7 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
6 Tegafur and uracil/tegafur + other agent
A27 OLCSG1b 27/41 21/42 100.0 % 1.79 [ 1.00, 3.20 ]
Subtotal (95% CI) 41 42 100.0 % 1.79 [ 1.00, 3.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.051)
7 Tegafur and uracil/tegafur
A28 OLCSG1a 30/163 28/158 10.8 % 0.99 [ 0.59, 1.66 ]
A29 WJSG2 (2+3) 38/108 49/100 16.0 % 0.63 [ 0.42, 0.97 ]
A30 WJSG4 38/176 56/191 17.4 % 0.78 [ 0.52, 1.17 ]
A31 NJSGLCS 24/109 27/110 9.5 % 0.90 [ 0.52, 1.56 ]
A32 OLCSG2a 20/85 35/87 10.2 % 0.58 [ 0.34, 0.99 ]
A33 ACTLC4b 17/52 18/52 6.5 % 0.94 [ 0.48, 1.82 ]
A34 JLCRG 67/498 91/501 29.5 % 0.74 [ 0.54, 1.02 ]
Subtotal (95% CI) 1191 1199 100.0 % 0.76 [ 0.64, 0.90 ]
Heterogeneity: Chi2 = 3.49, df = 6 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Chi2 = 12.25, df = 6 (P = 0.06), I2 =51%
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
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Analysis 2.1. Comparison 2 Surgery + radiotherapy versus surgery + radiotherapy + adjuvant
chemotherapy, Outcome 1 Survival.
Review: Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
Comparison: 2 Surgery + radiotherapy versus surgery + radiotherapy + adjuvant chemotherapy
Outcome: 1 Survival
Study or subgroup Treatment Control Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Platinum + vinca alkaloid/etoposide
B01 MSKCC 80-53 34/36 34/36 3.5 % 1.12 [ 0.69, 1.81 ]
B02 GETCB 01CB82 125/138 115/129 12.5 % 0.93 [ 0.72, 1.21 ]
B03 EORTC 08861 5/10 8/14 0.6 % 1.04 [ 0.34, 3.26 ]
B04 MDA DM 87045 15/16 18/18 1.7 % 0.84 [ 0.42, 1.67 ]
B05 INT 0115 183/246 186/242 19.5 % 0.96 [ 0.79, 1.18 ]
B06 ALPI2 136/238 146/232 14.9 % 0.87 [ 0.69, 1.10 ]
B07 IALT3 125/185 133/181 13.6 % 0.89 [ 0.70, 1.14 ]
B08 BLT4 15/23 18/26 1.7 % 0.94 [ 0.47, 1.89 ]
Subtotal (95% CI) 892 878 67.8 % 0.93 [ 0.83, 1.03 ]
Heterogeneity: Chi2 = 1.26, df = 7 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Platinum + vinorelbine
B09 ANITA2 104/176 139/201 12.8 % 0.70 [ 0.55, 0.90 ]
B10 IALT4 59/99 69/107 6.7 % 0.92 [ 0.65, 1.30 ]
Subtotal (95% CI) 275 308 19.5 % 0.77 [ 0.63, 0.94 ]
Heterogeneity: Chi2 = 1.46, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 2.51 (P = 0.012)
3 Other platinum regimen
B11 LCSG 791 68/82 75/90 7.5 % 0.85 [ 0.61, 1.18 ]
B12 FLCSG 3 34/40 42/46 4.0 % 0.84 [ 0.54, 1.33 ]
Subtotal (95% CI) 122 136 11.5 % 0.85 [ 0.65, 1.11 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
4 Antimetabolic agent only
B13 OLCSG1d 13/26 10/23 1.2 % 1.02 [ 0.45, 2.34 ]
Subtotal (95% CI) 26 23 1.2 % 1.02 [ 0.45, 2.34 ]
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(. . . Continued)
Study or subgroup Treatment Control Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 100.0 % 0.88 [ 0.81, 0.97 ]
Heterogeneity: Chi2 = 5.36, df = 12 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Chi2 = 2.63, df = 3 (P = 0.45), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
A D D I T I O N A L T A B L E S
Table 1. Recent meta-analyses of surgery (+/- radiotherapy) + chemotherapy versus surgery (+/- radiotherapy)
Author Type of data Number of trials Number of patients Outcome Hazard Ratio (95%
CI)
Hotta 2004 Published data 11* 5716 Survival 0.87 (0.81 to 0.94)
Sedrakyan 2004 Published data 19 7200 Survival 0.87 (0.81 to 0.93)
Berghmans 2005 Published data 17 7644 Survival 0.85 (0.79 to 0.91)
Bria 2005 Published data 11 + 1 meta-analysis 6494 Survival 0.93 (0.89 to 0.95)
Hamada 2005 Individual
participant data
6** 2003 Survival 0.74 (0.61 to 0.88)
Pignon 2008 Individual
participant data
5† 4584 Survival
Event-free survival
0.89 (0.82 to 0.96)
0.84 (0.78 to 0.91)
* Recent trials only
**UFT trials only
† Large (> 300 patients) and recent cisplatin trials only
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Table 2. Patient characteristics for trials of surgery + chemotherapy versus surgery and for trials of surgery + radiotherapy +
chemotherapy versus surgery + radiotherapy
Characteristic Surgery + CT*
(n = 4305)
Surgery
(n = 4142)
Surgery + RT** + CT
(n = 1315)
Surgery + RT
(n = 1345)
Age (years)
< 60 1827 (46%) 1669 (44%) 692 (53%) 693 (51%)
60 - 64 898 (17%) 900 (18%) 270 (20%) 292 (22%)
65 - 69 872 (20%) 878 (21%) 253 (19%) 253 (19%)
>= 70 593 (14%) 583 (14%) 100 (8%) 107 (8%)
Unknown 115 (3%) 112 (3%) - -
Sex
Male 2948 (68%) 2876 (69%) 1023 (78%) 1062 (79%)
Female 1238 (29%) 1149 (28%) 291 (22%) 281 (21%)
Unknown 119 (3%) 117 (3%) 1 (< 1%) 2 (< 1%)
Histology
Adenocarcinoma 2257 (52%) 2158(52%) 499 (38%) 501 (37%)
Squamous 1649 (38%) 1587 (38%) 642 (49%) 655 (49%)
Other 386 (9%) 391 (9%) 172 (13%) 184 (14%)
Unknown 13 (< 1%) 6 (< 1%) 2 (< 1%) 5 (< 1)
Stage
I 2851 (66%) 2772 (67%) 20 (2%) 14 (1%)
II 806 (19%) 793 (19%) 450 (34%) 473 (35%)
IIIa 586 (14%) 512 (12%) 804 (61%) 801 (60%)
IIIb 31 (< 1%) 42 (1%) 21 (2%) 30 (2%)
Stage III Unspecified - - - 3(<1%)
IV 13 (< 1%) 10 (< 1%) 3 (< 1%) 0 (0%)
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Table 2. Patient characteristics for trials of surgery + chemotherapy versus surgery and for trials of surgery + radiotherapy +
chemotherapy versus surgery + radiotherapy (Continued)
Unknown 18 (< 1%) 13 (< 1%) 17 (1%) 24 (2%)
Performance status†
Good 3172 (74%) 3022 (73%) 948 (72%) 969 (72%)
Poor 96 (2%) 83 (2%) 81 (6%) 105 (8%)
Unknown 76 (2%) 58 (1%) 22 (2%) 16 (1%)
Not supplied 961 (22%) 979 (24%) 264 (20%) 255 (19%)
Extent of resection
Complete 4119 (96%) 3951 (95%) 1097 (83%) 1121 (83%)
Incomplete 120 (3%) 123 (3%) 179 (14%) 186 (14%)
Unknown 66 (1%) 68 (2%) 39 (3%) 38 (3%)
Radiotherapy timing
CT before RT - - 941 (72%) 963 (72%)
Concomitant CT + RT - - 374 (28%) 382 (28%)
*CT = Chemotherapy
**RT = Radiotherapy
†Good = 0,1 ECOG/WHO or 100 - 70 Karnofsky; Poor > 2 ECOG/OMS or <= 60 Karnofsky
A P P E N D I C E S
Appendix 1. MEDLINE Search Strategy
Cochrane Highly Sensitive Search Strategy for identifying RCTs (MEDLINE) (Lefebvre 2008)
1. “randomi*ed controlled trial”.pt.
2. controlled clinical trial.pt.
3. “randomi*ed”.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
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10. (animals not (humans and animals)).sh.
11. 9 not 10
Terms specific to lung cancer:
12. exp Lung Neoplasms/
13. exp Carcinoma, Non-Small-Cell Lung/
14. (lung$ adj3 canc$).mp.
15. (lung$ adj3 carcinoma$).mp.
16. (lung$ adj3 tumo?r$).mp.
17. (lung$ adj3 neoplasm$).mp.
18. 12 or 13 or 14 or 15 or 16 or 17
Terms specific to the intervention:
19. exp Drug Therapy/
20. chemotherapy.mp.
21. 19 or 20
22. exp Radiotherapy/
23. radiotherapy.mp.
24. 22 or 23
25. exp General Surgery/
26. surgery.mp.
27. 25 or 26
28. 21 or 24 or 27
29. 11 and 18 and 28
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